Strategies to consider to improve the slow progress in ER+ve BC and the risk of relapse

Regarder maintenant Strategies to consider to improve the slow progress in ER+ve BC and the risk of relapse

Trans-aTTom: To offer more?

Regarder maintenant Trans-aTTom: To offer more?

Neoadjuvant vs adjuvant approaches in early TNBC

Regarder maintenant Neoadjuvant vs adjuvant approaches in early TNBC

Canadian Perspective on Overall survival (OS) in KATE2.

Regarder maintenant Canadian Perspective on Overall survival (OS) in KATE2.

KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.

Regarder maintenant KEYNOTE-119: Phase 3 study of pembrolizumab versus single-agent chemotherapy for metastatic triple-negative breast cancer.